Published online before print January 15, 2004, doi: 10.1161/01.STR.0000114202.86942.61
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2004;35:e39.)
© 2004 American Heart Association, Inc.
Research Reports |
Prospective Evaluation of the Alcohol Dehydrogenase 
1/2 Gene Polymorphism and Risk of Stroke
From the Center for Cardiovascular Disease Prevention and the Division of Preventive Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass.
Correspondence to Robert Y.L. Zee, PhD, Brigham & Women’s Hospital, 900 Commonwealth Avenue East, Boston, MA 02215. E-mail rzee{at}rics.bwh.harvard.edu
 |
Abstract |
|---|
 Top Abstract IntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
Background and Purpose— Genetic polymorphism of the alcohol dehydrogenase type 3 gene (ADH1C) has recently been associated with reduced risk of myocardial infarction. However, data on risk of stroke are not available.
Methods— We examined the possible association between the ADH1C 
1/2 polymorphism and risk of stroke in a prospective, nested case-control sample from the Physicians’ Health Study of 14 916 apparently healthy men who were followed over a 12-year period. A total of 320 incident stroke cases and 550 age- and smoking-matched controls were genotyped.
Results— All observed genotype frequencies were in Hardy-Weinberg equilibrium. The allele and genotype distributions of the polymorphism tested were similar between cases and controls, such that the relative risk of stroke was 1.04 for ADH1C 1/2 (95% CI=0.85 to 1.28; P=0.65) assuming an additive mode of inheritance. Contrary to prior findings for myocardial infarction, no evidence of association was observed to suggest an effect modification of ADH1C genotypes with the level of alcohol consumption on the risk of stroke. Similar findings were observed in subgroup analysis restricted to ischemic events.
Conclusions— In this large, prospective study, we found little evidence that the ADH1C 1/2 polymorphism is associated with risk of future stroke. These data raise the possibility of important pathologic differences in ischemia between the coronary and cerebral circulations.
Key Words: ADH1C • prospective studies • risk factors • stroke
|
Introduction |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
Stroke, a major cause of permanent disability, has serious public health complications in developed countries. Several studies have reported an association of light to moderate alcohol consumption with reduced risk of cardiovascular diseases including stroke,1–4 whereas others found an increased risk of stroke with alcohol intake.5,6 A recent meta-analysis of experimental studies has concluded that heavy alcohol consumption increases the relative risk of stroke while light to moderate alcohol consumption may be protective against total and ischemic stroke.7
The class I alcohol dehydrogenase (ADH) enzymes, including ADH type 3, are mainly involved in ethanol oxidation. Genetic variants have been found for the ADH type 3 (ADH1C) locus, resulting in 1 and 2 isoenzymes.8 The 1 subunit differs from 2 subunit by 2 amino acid substitutions: arginine (R) for glutamine (Q) at position 271, and isoleucine (I) for valine (V) at position 349.8 Pharmacokinetic studies have shown that the 1 isoenzyme is associated with a fast rate of ethanol oxidation while the 2 isoenzyme with a slow rate of ethanol oxidation.9 Interestingly, the ADH1C 2 allele has recently been associated with reduced risk of myocardial infarction (MI), and importantly, to interact with alcohol consumption.10 However, to date, no data are available for the risk of stroke. We therefore investigated the role of the ADH1C 1/2 polymorphism as a risk marker for stroke in the Physicians’ Health Study (PHS).
|
Subjects and Methods |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
We employed a nested case-control design within the PHS, a randomized, double-blinded, placebo-controlled trial of aspirin and beta-carotene initiated in 1982 among 22 071 male, predominantly white, US physicians, 40 to 84 years of age at study entry.11 Before randomization, 14 916 participants provided an EDTA-anticoagulated blood sample and stored for genetic analysis. All participants were free of prior MI, stroke, transient ischemic attacks, and cancer at study entry. Yearly follow-up self-report questionnaires provided reliable updated information11 on newly developed diseases and the presence or absence of other cardiovascular risk factors. History of cardiovascular risk factors, such as hypertension, diabetes, or hypercholesterolemia, was defined by self-report of diagnosis at entry into the study.
Stroke was defined by the presence of a new focal neurological deficit, with symptoms and signs persisting for >24 hours, and was ascertained from blinded review of medical records, autopsy results, and the judgment of a board-certified neurologist. Stroke was classified as ischemic, hemorrhagic, or unknown, on the basis of clinical reports, computed tomographic (CT), or magnetic resonance image (MRI) scanning. For the present investigation, 320 incident cases of stroke were identified among those study participants who had stored blood samples.
For each case, 1 or more controls (if available) matched by age, smoking history, and length of follow-up were chosen among those subjects who remained free of vascular diseases (a total of 550 controls). The study was approved by the Brigham and Women’s Hospital Institutional Review Board for Human Subjects Research.
Genotype Determination
Details of genotype determination have been described previously.12 In brief, the ADH1C 1/2 isoenzyme-polymorphism was determined by polymerase chain reaction–restriction fragment length polymorphism gel electrophoresis. To confirm genotype assignment, scoring was carried out by 2 independent observers. Discordant results (<2% of all scoring) were resolved by a joint reading and, where necessary, a repeat genotyping. Results were scored blinded as to case-control status.
Statistical Analysis
Allele and genotype frequencies among cases and controls were compared with values predicted by Hardy-Weinberg equilibrium using the 
2 test. Relative risks of stroke associated with each genotype, with 95% confidence intervals (CI), were calculated by logistic regression analysis conditioning on the matching by age, smoking status, and length of follow-up since randomization, and further controlling for randomized treatment assignment, hypertension, diabetes, BMI, and level of alcohol consumption. Conditional logistic regression was also used to detect possible effect modification of ADH1C genotypes on the relation between the level of alcohol consumption and the risk of stroke by incorporating interaction terms for each category of alcohol consumption and each genotype. The probability values for trends were determined based on the Wald test. All probability values were 2-tailed.
|
Results |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
Baseline characteristics of stroke cases and controls are shown in Table 1. As expected, the case participants had a higher prevalence of hypertension, and diabetes at baseline as compared with controls. As also shown in Table 1, the allele and genotype frequencies were similar between cases and controls. The allele and genotype frequencies for the study population were in Hardy-Weinberg equilibrium.
|
Although statistically nonsignificant, we observed a trend of risk reduction among men according to the level of alcohol consumption (Table 2). As compared with men who were classified as rare or nondrinkers, men who were classified as monthly drinkers had a relative risk of 0.89, 95% CI 0.54 to 1.50; men classified as weekly drinkers had a relative risk of 0.72, 95% CI 0.49 to 1.06; and men classified as daily drinkers had a relative risk of 0.73, 95% CI 0.48 to 1.11; P for trend=0.10. The level of alcohol consumption did not modify the association between the ADH1C genotype and the risk of stroke (Table 3). Similar null findings were obtained in analyses limited to ischemic events.
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
In this large, prospective investigation, we found no evidence of association between the ADH1C
1/2 polymorphism and risk of stroke, either in the total cohort or in subgroup analysis limited to ischemic events. Furthermore, we found little evidence of effect modification or interaction of the variant tested with the level of alcohol consumption on the risk of stroke. The current null findings are in contrast to a previous report in this cohort,10 which suggested the ADH1C 1/2 polymorphism as a protective factor against the risk of MI.
We believe chance is an unlikely explanation of this difference for 2 reasons. First, the background allele frequency of the ADH1C polymorphism tested is virtually identical in our nested case-control study and in the previous report by Hines et al,10 thus greatly reducing the possibility of misclassification bias. Second, in our study, we had the ability to detect, with 80% power, at an alpha of 0.05, a risk ratio of >1.35 for 2 allelic variant with stroke assuming an additive model. By contrast, we believe that the observed difference between studies reflects a relative differential contribution of traditional risk factors between MI and cerebrovascular event. In particular, while LDL cholesterol is an important risk factor for MI, lipid levels are poor predictors of stroke,13 and thus effects of alcohol mediated through lipid changes may be less important for stroke. Conversely, hypertension and diabetes are relatively more powerful predictors of stroke. Several speculative explanations have been suggested including nonclassic atherosclerotic mechanisms and differential effect of plasma lipids on atherogenesis in the intracranial vasculature.13 Thus, if there are as yet unidentified environmental modifiers of the ADH1C gene effect on atherothrombosis, these gene-environment interactions may well differ between MI and stroke.
In conclusion, in this large, prospective, nested case-control study among middle-aged US men, we found no evidence of association between the ADH1C polymorphism tested and the risk of stroke, nor any evidence of an effect modification with the level of alcohol consumption on the risk of stroke. These data contrast with those for MI previously observed in this cohort and thus raise the possibility of important pathophysiologic differences between ischemia in the coronary and cerebral vasculatures.
|
Acknowledgments |
|---|
This study was supported by the National Heart, Lung, and Blood Institute (HL58755, HL63293), the American Heart Association, and the Doris Duke Charitable Foundation (P.M.R.).
Received September 15, 2003; accepted October 29, 2003.
|
References |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
1. Gaziano JM, Buring JE, Breslow JL, Goldhaber SZ, Rosner B, VanDenburgh M, Willett W, Hennekens CH. Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. N Engl J Med. 1993; 329: 1829–1834.
2. Berger K, Ajani UA, Kase CS, Gaziano JM, Buring JE, Glynn RJ, Hennekens CH. Light-to-moderate alcohol consumption and risk of stroke among U.S. male physicians. N Engl J Med. 1999; 341: 1557–1564.
3. Mukamal KJ, Jadhav PP, D’Agostino RB, Massaro JM, Mittleman MA, Lipinska I, Sutherland PA, Matheney T, Levy D, Wilson PW, et al. Alcohol consumption and hemostatic factors: analysis of the Framingham Offspring cohort. Circulation. 2001; 104: 1367–1373.
4. Djousse L, Ellison RC, Beiser A, Scaramucci A, D’Agostino RB, Wolf PA. Alcohol consumption and risk of ischemic stroke: the Framingham Study. Stroke. 2002; 33: 907–912;published erratum, 2002; 33: 1727.
5. Hansagi H, Romelsjo A, Gerhardsson de Verdier M, Andreasson S, Leifman A. Alcohol consumption and stroke mortality: 20-year follow-up of 15,077 men and women. Stroke. 1995; 26: 1768–1773.
6. Wannamethee SG, Shaper AG. Patterns of alcohol intake and risk of stroke in middle-aged British men. Stroke. 1996; 27: 1033–1039.
7. Reynolds K, Lewis LB, Nolen JD, Kinney GL, Sathya B, He J. Alcohol consumption and risk of stroke: a meta-analysis. JAMA. 2003; 289: 579–588.
8. Hoog JO, Heden LO, Larsson K, Jornvall H, von Bahr-Lindstrom H. The gamma 1 and gamma 2 subunits of human liver alcohol dehydrogenase: cDNA structures, two amino acid replacements, and compatibility with changes in the enzymatic properties. Eur J Biochem. 1986; 159: 215–218.[Medline] [Order article via Infotrieve]
9. Bosron WF, Lumeng L, Li TK. Genetic polymorphism of enzymes of alcohol metabolism and susceptibility to alcoholic liver disease. Mol Aspects Med. 1988; 10: 147–158.[CrossRef][Medline] [Order article via Infotrieve]
10. Hines LM, Stampfer MJ, Ma J, Gaziano JM, Ridker PM, Hankinson SE, Sacks F, Rimm EB, Hunter DJ. Genetic variation in alcohol dehydrogenase and the beneficial effect of moderate alcohol consumption on myocardial infarction. N Engl J Med. 2001; 344: 549–555.
11. Steering committee of the physicians’ health study research group. Final report of the aspirin component of the ongoing physicians’ health study. N Engl J Med. 1989; 312: 129–135.
12. Groppi A, Begueret J, Iron A. Improved methods for genotype determination of human alcohol dehydrogenase (ADH) at ADH 2 and ADH 3 loci by using polymerase chain reaction-directed mutagenesis. Clin Chem. 1990; 36: 1765–1768.
13. Shahar E, Chambless LE, Rosamond WD, Boland LL, Ballantyne CM, McGovern PG, Sharrett AR. Atherosclerosis Risk in Communities Study. Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2003; 34: 623–631.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||